Drug-Free Nanoparticles Stop Aggressive Breast Cancer in Mice

Scientists just found a way to fight one of the deadliest forms of breast cancer without using a single drug.

Researchers at Technion-Israel Institute of Technology created nanoparticles called MPsomes that successfully halted aggressive triple-negative breast cancer in mice. The treatment works entirely without chemotherapy or medication, using only the body's natural immune system.

Triple-negative breast cancer accounts for just 13% of all breast cancers but causes 40% of breast cancer deaths. It's called triple-negative because it lacks three key markers that make other cancers treatable with hormone therapy, leaving patients with limited options.

The innovation targets how cancer hijacks the body. Tumors recruit white blood cells called macrophages, which normally fight infections, and trick them into feeding the tumor instead of attacking it.

Assistant Professor Assaf Zinger and his team designed nanoparticles that flood around tumors and block these hijacked macrophages. Once blocked, other immune cells can move in and shrink the tumors naturally.

In lab testing on mice and cell cultures, the MPsomes stopped tumor growth without harming vital organs. The team can manufacture one liter of these particles in just one hour.

Even better, the particles use materials already classified as safe by international regulators. This could speed up the path to human clinical trials, though Zinger acknowledges frustration with the long road ahead.

"We know how to cure cancer in mice," Zinger said. "Now let's focus on people."

Why This Inspires

This research shows what happens when scientists think differently about cancer treatment. Instead of attacking cancer cells directly with toxic chemicals, the Technion team found a way to simply stop the tumor's support system.

Professor Avi Schroeder, who wasn't involved in the research, called the approach "unique" and said it "brings fresh hope to patients battling breast cancer and other cancers too."

Every year, roughly 2.3 million women worldwide are diagnosed with breast cancer, and 670,000 die from it. In Israel alone, about 900 women die annually from the disease.

Zinger's team is already developing similar nanoparticles for other conditions, including pediatric brain diseases, traumatic brain injuries, and ovarian cancer. He invites cancer survivors to speak with his students each year to remind them why their work matters.

The path from successful mouse trials to helping people is long and uncertain, but this drug-free approach opens a door that didn't exist before.